Navigation Links
ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
Date:6/24/2009

ADDISON, Texas, June 24 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) today announced that at this time discussions to acquire York Pharma, plc, a public limited company incorporated under the laws of England and Wales ("York") have been terminated. Previously it had been announced that ULURU intended to proceed with an offer to acquire all of the issued share capital of York, as described in the non-binding offer letter that ULURU and York signed on April 6, 2009. ULURU has notified York that all amounts owing to ULURU under the secured revolving credit facility established pursuant to that certain Note Purchase Agreement dated March 31, 2009 by and between ULURU and York, which amounts total US$1,000,000, plus all accrued but unpaid interest, are due and payable in accordance with the terms of such facility. This revolving credit facility is secured by substantially all of the assets of York and its subsidiaries.

Despite this termination of discussions with York, ULURU remains committed to pursuing strategic opportunities and partnerships in the near future.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and transmucosal delivery system. For more information about Altrazeal(TM), please visit www.Altrazeal.com. For more information about ULURU Inc., please visit www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the possible acquisition of York by the Company and statements relating to potential strategic benefits of any such acquisition. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat E. Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ULURU to Present Clinical Evidence and Advanced Research on Altrazeal at the Society for Advance Wound Care Conference for 2009
2. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
3. ULURU Inc. Reports Second Quarter 2008 Financial Results
4. ULURU Inc. Announces Update on Recent Development
5. ULURU Inc. to Present at the 8th World Biomaterials Congress
6. Icahn Asks Amylin to Allow Discussions With Eastbourne
7. Kiwa Bio-Tech in Collaboration Discussions with Beijing Hai Xin Science and Technology Co., Ltd.
8. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
9. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
10. Biopure Gives Update on Malaysia Joint Venture Discussions
11. Solon Manufacturing Company Acquires PurFybr Brands; Adds Influenza Virus Diagnostic Swabs to Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):